MDT Stock Forecast 2025-2026
Distance to MDT Price Targets
MDT Price Momentum
10 Quality Stocks Worth Considering Now
Researching Medtronic (MDT) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on MDT and similar high-potential opportunities.
Latest MDT Stock Price Targets & Analyst Predictions
Based on our analysis of 31 Wall Street analysts, MDT has a neutral consensus with a median price target of $95.00 (ranging from $85.00 to $112.46). The overall analyst rating is Buy (7.5/10). Currently trading at $88.23, the median forecast implies a 7.7% upside. This outlook is supported by 16 Buy, 14 Hold, and 2 Sell ratings.
Conversely, the most conservative target is provided by Rick Wise at Stifel, suggesting a 3.7% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
MDT Analyst Ratings
MDT Price Target Range
Latest MDT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for MDT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 4, 2025 | Citigroup | Joanne Wuensch | Buy | Upgrade | $107.00 |
| Feb 19, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Feb 19, 2025 | UBS | Danielle Antalffy | Neutral | Maintains | $95.00 |
| Feb 19, 2025 | RBC Capital | Shagun Singh | Outperform | Reiterates | $105.00 |
| Feb 19, 2025 | Baird | David Rescott | Neutral | Maintains | $91.00 |
| Feb 12, 2025 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Dec 18, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $89.00 |
| Nov 26, 2024 | Barclays | Matt Miksic | Overweight | Maintains | $109.00 |
| Nov 20, 2024 | Bernstein | Lee Hambright | Outperform | Maintains | $97.00 |
| Nov 20, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Nov 20, 2024 | Wells Fargo | Larry Biegelsen | Overweight | Maintains | $98.00 |
| Nov 20, 2024 | Baird | David Rescott | Neutral | Maintains | $93.00 |
| Nov 18, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 25, 2024 | Needham | Mike Matson | Hold | Reiterates | $0.00 |
| Oct 14, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $93.00 |
| Oct 10, 2024 | RBC Capital | Shagun Singh | Outperform | Upgrade | $105.00 |
| Oct 8, 2024 | RBC Capital | Shagun Singh | Sector Perform | Maintains | $98.00 |
| Oct 1, 2024 | Evercore ISI Group | Vijay Kumar | Outperform | Maintains | $104.00 |
| Oct 1, 2024 | Citigroup | Joanne Wuensch | Neutral | Maintains | $92.00 |
| Aug 23, 2024 | Truist Securities | Richard Newitter | Hold | Maintains | $90.00 |
Medtronic plc (MDT) Competitors
The following stocks are similar to Medtronic based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Medtronic plc (MDT) Financial Data
Medtronic plc has a market capitalization of $113.16B with a P/E ratio of 26.9x. The company generates $33.20B in trailing twelve-month revenue with a 12.8% profit margin.
Revenue growth is +2.5% quarter-over-quarter, while maintaining an operating margin of +21.9% and return on equity of +8.4%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Medtronic plc (MDT) Business Model
About Medtronic plc
Global healthcare technology company providing medical devices.
Medtronic generates revenue by designing, manufacturing, and selling a diverse range of medical devices and therapies across various medical fields, including cardiovascular, diabetes management, and neurosurgery. The company focuses on innovative solutions that enhance patient outcomes and healthcare efficiency.
Founded in 1949 and headquartered in Dublin, Ireland, Medtronic is a leader in the medical device industry, known for its pacemaker technology. The company invests heavily in research and development to advance medical technology and set industry standards, impacting patient care worldwide.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
95,000
CEO
Mr. Geoffrey Straub Martha
Country
Ireland
IPO Year
1981
Website
www.medtronic.comMedtronic plc (MDT) Latest News & Analysis
Medtronic's Hypertension business is set for significant expansion due to the success of its Simplicity blood pressure procedure.
Medtronic's expansion in the hypertension market could significantly boost revenue and market share, enhancing investor confidence and potentially increasing stock value.
Five AI-powered stocks with strong revenue and earnings growth potential for 2025 are MDT, LLY, BSX, NVS, and ABT.
Strong revenue and earnings growth potential in AI-powered stocks indicates possible future profitability and market performance, influencing investment strategies and portfolio decisions.
Medtronic (MDT) reported earnings 30 days ago; investors may be looking for insights into future stock performance following this announcement.
Upcoming developments for Medtronic could impact stock performance, affecting investor sentiment and potential price movements based on earnings trends and market expectations.
Medtronic (MDT) is currently attracting significant interest from Zacks.com users, highlighting factors that could influence its stock performance.
Increased attention on Medtronic from Zacks.com users may signal heightened investor interest, potentially affecting stock volatility and future performance.
The FDA classified Medtronic's embolization device recall as "most serious" after reports of four patient deaths.
The FDA's classification of Medtronic's device recall as "most serious" raises concerns about safety, potential lawsuits, and impacts on sales, affecting the company's stock performance and investor sentiment.
Zacks Premium offers Style Scores, aiding value, growth, and momentum investors in identifying strong stocks more effectively.
Zacks Style Scores can help investors identify strong stocks across different strategies, potentially enhancing portfolio performance and decision-making.
Frequently Asked Questions About MDT Stock
What is Medtronic plc's (MDT) stock forecast for 2025?
Based on our analysis of 31 Wall Street analysts, Medtronic plc (MDT) has a median price target of $95.00. The highest price target is $112.46 and the lowest is $85.00.
Is MDT stock a good investment in 2025?
According to current analyst ratings, MDT has 16 Buy ratings, 14 Hold ratings, and 2 Sell ratings. The stock is currently trading at $88.23. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for MDT stock?
Wall Street analysts predict MDT stock could reach $95.00 in the next 12 months. This represents a 7.7% increase from the current price of $88.23. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Medtronic plc's business model?
Medtronic generates revenue by designing, manufacturing, and selling a diverse range of medical devices and therapies across various medical fields, including cardiovascular, diabetes management, and neurosurgery. The company focuses on innovative solutions that enhance patient outcomes and healthcare efficiency.
What is the highest forecasted price for MDT Medtronic plc?
The highest price target for MDT is $112.46 from at , which represents a 27.5% increase from the current price of $88.23.
What is the lowest forecasted price for MDT Medtronic plc?
The lowest price target for MDT is $85.00 from Rick Wise at Stifel, which represents a -3.7% decrease from the current price of $88.23.
What is the overall MDT consensus from analysts for Medtronic plc?
The overall analyst consensus for MDT is neutral. Out of 31 Wall Street analysts, 16 rate it as Buy, 14 as Hold, and 2 as Sell, with a median price target of $95.00.
How accurate are MDT stock price projections?
Stock price projections, including those for Medtronic plc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
